vs
Community Healthcare Trust Inc（CHCT）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Community Healthcare Trust Inc的1.1倍（$35.5M vs $30.9M），Community Healthcare Trust Inc净利率更高（46.6% vs -304.2%，领先350.9%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 5.6%），Community Healthcare Trust Inc自由现金流更多（$35.9M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 2.7%）
医疗物业信托（MPT）是一家总部位于美国阿拉巴马州伯明翰的国际房地产投资信托（REIT）企业，主要在美国和欧洲地区收购投资医疗设施与营利性医疗控股公司。该公司多数物业收购以售后回租形式完成：原物业所有者将物业出售给MPT后，转而成为MPT的租户，租户通常签订长期三净租赁合约。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CHCT vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.9M | $35.5M |
| 净利润 | $14.4M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 46.6% | -304.2% |
| 营收同比 | 5.6% | 681.7% |
| 净利润同比 | 687.6% | 39.6% |
| 每股收益（稀释后） | $0.52 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $30.9M | $35.5M | ||
| Q3 25 | $31.1M | $5.2M | ||
| Q2 25 | $29.1M | $19.2M | ||
| Q1 25 | $30.1M | $14.7M | ||
| Q4 24 | $29.3M | $4.5M | ||
| Q3 24 | $29.6M | $26.1M | ||
| Q2 24 | $27.5M | $14.4M | ||
| Q1 24 | $29.3M | $13.8M |
| Q4 25 | $14.4M | $-108.1M | ||
| Q3 25 | $1.6M | $-162.3M | ||
| Q2 25 | $-12.6M | $-171.9M | ||
| Q1 25 | $1.6M | $-202.5M | ||
| Q4 24 | $1.8M | $-178.9M | ||
| Q3 24 | $1.7M | $-95.8M | ||
| Q2 24 | $-10.4M | $-97.5M | ||
| Q1 24 | $3.7M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | — | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | — | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
| Q4 25 | 46.6% | -304.2% | ||
| Q3 25 | 5.3% | -3135.3% | ||
| Q2 25 | -43.2% | -894.2% | ||
| Q1 25 | 5.3% | -1373.3% | ||
| Q4 24 | 6.3% | -3935.5% | ||
| Q3 24 | 5.9% | -367.5% | ||
| Q2 24 | -37.9% | -676.6% | ||
| Q1 24 | 12.5% | -662.4% |
| Q4 25 | $0.52 | $-0.17 | ||
| Q3 25 | $0.03 | $-0.36 | ||
| Q2 25 | $-0.50 | $-0.41 | ||
| Q1 25 | $0.03 | $-0.50 | ||
| Q4 24 | $0.04 | $-0.56 | ||
| Q3 24 | $0.04 | $-0.34 | ||
| Q2 24 | $-0.42 | $-0.40 | ||
| Q1 24 | $0.11 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.3M | $743.3M |
| 总债务越低越好 | $532.2M | $9.6M |
| 股东权益账面价值 | $429.4M | $1.1B |
| 总资产 | $990.8M | $1.5B |
| 负债/权益比越低杠杆越低 | 1.24× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $3.3M | $743.3M | ||
| Q3 25 | $3.4M | $659.8M | ||
| Q2 25 | $4.9M | $525.1M | ||
| Q1 25 | $2.3M | $500.5M | ||
| Q4 24 | $4.4M | $594.4M | ||
| Q3 24 | $2.8M | $427.6M | ||
| Q2 24 | $734.0K | $474.3M | ||
| Q1 24 | $3.8M | $296.3M |
| Q4 25 | $532.2M | $9.6M | ||
| Q3 25 | $530.1M | $11.9M | ||
| Q2 25 | $500.1M | $14.2M | ||
| Q1 25 | $496.0M | $16.4M | ||
| Q4 24 | $486.0M | $19.0M | ||
| Q3 24 | $473.7M | $20.5M | ||
| Q2 24 | $457.6M | $22.9M | ||
| Q1 24 | $442.3M | — |
| Q4 25 | $429.4M | $1.1B | ||
| Q3 25 | $426.8M | $1.0B | ||
| Q2 25 | $437.8M | $919.1M | ||
| Q1 25 | $461.3M | $933.9M | ||
| Q4 24 | $476.0M | $1.0B | ||
| Q3 24 | $477.2M | $524.6M | ||
| Q2 24 | $497.8M | $584.4M | ||
| Q1 24 | $511.6M | $401.2M |
| Q4 25 | $990.8M | $1.5B | ||
| Q3 25 | $987.3M | $1.4B | ||
| Q2 25 | $966.3M | $1.3B | ||
| Q1 25 | $985.1M | $1.3B | ||
| Q4 24 | $992.6M | $1.4B | ||
| Q3 24 | $981.8M | $726.5M | ||
| Q2 24 | $983.2M | $775.9M | ||
| Q1 24 | $982.7M | $557.8M |
| Q4 25 | 1.24× | 0.01× | ||
| Q3 25 | 1.24× | 0.01× | ||
| Q2 25 | 1.14× | 0.02× | ||
| Q1 25 | 1.08× | 0.02× | ||
| Q4 24 | 1.02× | 0.02× | ||
| Q3 24 | 0.99× | 0.04× | ||
| Q2 24 | 0.92× | 0.04× | ||
| Q1 24 | 0.86× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $56.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $35.9M | $-47.3M |
| 自由现金流率自由现金流/营收 | 116.0% | -133.1% |
| 资本支出强度资本支出/营收 | 66.3% | 3.5% |
| 现金转化率经营现金流/净利润 | 3.91× | — |
| 过去12个月自由现金流最近4个季度 | $62.8M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $56.4M | $-46.1M | ||
| Q3 25 | $12.7M | $-117.4M | ||
| Q2 25 | $13.8M | $-76.4M | ||
| Q1 25 | $14.4M | $-132.0M | ||
| Q4 24 | $58.9M | $-115.4M | ||
| Q3 24 | $13.8M | $-59.2M | ||
| Q2 24 | $16.7M | $-82.2M | ||
| Q1 24 | $12.6M | $-102.3M |
| Q4 25 | $35.9M | $-47.3M | ||
| Q3 25 | $7.6M | $-117.6M | ||
| Q2 25 | $9.6M | $-79.6M | ||
| Q1 25 | $9.7M | $-133.8M | ||
| Q4 24 | $34.2M | $-116.7M | ||
| Q3 24 | $6.7M | $-63.8M | ||
| Q2 24 | $9.5M | $-83.4M | ||
| Q1 24 | $7.5M | $-109.0M |
| Q4 25 | 116.0% | -133.1% | ||
| Q3 25 | 24.6% | -2272.5% | ||
| Q2 25 | 32.9% | -413.9% | ||
| Q1 25 | 32.3% | -907.4% | ||
| Q4 24 | 116.9% | -2567.7% | ||
| Q3 24 | 22.5% | -244.6% | ||
| Q2 24 | 34.7% | -578.5% | ||
| Q1 24 | 25.7% | -789.9% |
| Q4 25 | 66.3% | 3.5% | ||
| Q3 25 | 16.3% | 4.7% | ||
| Q2 25 | 14.5% | 16.4% | ||
| Q1 25 | 15.6% | 12.4% | ||
| Q4 24 | 84.1% | 28.6% | ||
| Q3 24 | 24.2% | 17.5% | ||
| Q2 24 | 26.1% | 8.2% | ||
| Q1 24 | 17.4% | 48.2% |
| Q4 25 | 3.91× | — | ||
| Q3 25 | 7.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.06× | — | ||
| Q4 24 | 32.14× | — | ||
| Q3 24 | 7.92× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
